Clinical trial · Interventional
Cryoablation of Low Risk Small Breast Cancer- ICE3 Trial
Cryoablation of Low Risk Breast Cancer Less Than 1.5 cm: An Evaluation of Local Recurrence (Ice3 Trial)
NCT02200705CI-TRIAL-00117024completedN/AResults postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To evaluate the efficacy of cryoablation without lumpectomy and its impact on local and distant recurrence of early stage breast cancer .
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Ice-Sense3TM/ ProSenseTM | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- single arm, open label
- description
- Early stage Breast cancers up to 1.5cm
- interventionNames
- Device: Ice-Sense3TM/ ProSenseTM
Primary outcomes (1)
- measure
- Local Inbreast Breast Tumor Recurrence (IBTR) Rate
- timeFrame
- up to 5 years
- description
- 6 months post cryoabltion, then annually for 5 years
Secondary outcomes (8)
- measure
- Complete Primary Tumor Ablation Rate
- timeFrame
- up to 5 years from procedure date.
- description
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 50 Years
Show eligibility criteria text
Inclusion Criteria: 1. Competent to sign informed consent 2. Diagnosis of invasive ductal breast carcinoma by core needle biopsy, meeting the following criteria: 1. Unifocal primary disease NOTE: Patients with multifocal and/or multicentric in breast cancer, or evidence of EIC are NOT eligible. Patients with contralateral disease will remain eligible. 2. Tumor size ≤1.5 cm in greatest diameter in the axis parallel to the treatment probe AND ≤1.5 cm in the axis anti-parallel to the treatment probe AND ≤1.5 cm in Anterior/ Posterior dimension. Tumor size ≤1.5 cm in greatest diameter as measured by breast ultrasound, mammogram and/or MRI. The largest dimension measured will be used to determine eligibility. 3. Nottingham grade 1-2. Specifically, nuclear and mitotic scores must be less than or equal to 2. 4. Estrogen receptor-positive, progesterone receptor-positive, HER2 negative 3. Age\>= 50 4. Breast size adequate for safe cryoablation 5. Lesion must be sonographically visible at the time of treatment. 6. History of previously treated ipsilateral or contralateral breast carcinoma is not an exclusion criteria if the investigator is certain newly diagnosed carcinoma is new unifocal primary tumor. Exclusion Criteria: 1. Presence of lobular carcinoma 2. Presence of luminal B pathology 3. Nottingham score of 3 (specially nuclear and mitotic score\>2) 4. Presence of microinvasion, or invasive breast carcinoma with extensive intraductal component (EIC) 5. Presence of multifocal and/or multicentric in breast cancer 6. Presence of multifocal calcifications 7. Presence of prior or concurrent neoadjuvant chemotherapy for breast cancer 8. Presence of prior en bloc open surgical biopsy and/or lumpectomy for diagnosis/treatment of the index breast cancer 9. Patient that is not suitable to cryoablation procedure according to the physician opinion 10. ER AND PR negative, or Her2 positive noted on pre-cryo biopsy
References
Publications (1)
- DERIVEDJean J, Jochelson MS, Moo TA, Solomon SB, Bryce Y. Breast Cancer Recurrence after Cryoablation in Patients Who Are Poor Surgical Candidates or Who Refuse Surgery. J Vasc Interv Radiol. 2025 Jun;36(6):971-978. doi: 10.1016/j.jvir.2025.01.048. Epub 2025 Feb 3. PMID 39909175